Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023

Author's Avatar
May 25, 2023

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on May 31, 2023 at 8:30 AM ET.